FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2923367087> ?p ?o ?g. }

• W2923367087 endingPage "14" @default.
• W2923367087 startingPage "1" @default.
• W2923367087 abstract "PURPOSE Third-generation epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) are effective in acquired resistance (AR) to early-generation EGFR TKIs in EGFR-mutant lung cancer. However, efficacy is marked by interindividual heterogeneity. We present the molecular profiles of pretreatment and post-treatment samples from patients treated with third-generation EGFR TKIs and their impact on treatment outcomes. METHODS Using the databases of two lung cancer networks and two lung cancer centers, we molecularly characterized 124 patients with EGFR p.T790M-positive AR to early-generation EGFR TKIs. In 56 patients, correlative analyses of third-generation EGFR TKI treatment outcomes and molecular characteristics were feasible. In addition, matched post-treatment biopsy samples were collected for 29 patients with progression to third-generation EGFR TKIs. RESULTS Co-occurring genetic aberrations were found in 74.4% of EGFR p.T790-positive samples (n = 124). Mutations in TP53 were the most frequent aberrations detected (44.5%; n = 53) and had no significant impact on third-generation EGFR TKI treatment. Mesenchymal-epithelial transition factor ( MET) amplifications were found in 5% of samples (n = 6) and reduced efficacy of third-generation EGFR TKIs significantly (eg, median progression-free survival, 1.0 months; 95% CI, 0.37 to 1.72 v 8.2 months; 95% CI, 1.69 to 14.77 months; P ≤ .001). Genetic changes in the 29 samples with AR to third-generation EGFR TKIs were found in EGFR (eg, p.T790M loss, acquisition of p.C797S or p.G724S) or in other genes (eg, MET amplification, KRAS mutations). CONCLUSION Additional genetic aberrations are frequent in EGFR-mutant lung cancer and may mediate innate and AR to third-generation EGFR TKIs. MET amplification was strongly associated with primary treatment failure and was a common mechanism of AR to third-generation EGFR TKIs. Thus, combining EGFR inhibitors with TKIs targeting common mechanisms of resistance may delay AR." @default.
• W2923367087 created "2019-04-01" @default.
• W2923367087 creator A5000668683 @default.
• W2923367087 creator A5002306737 @default.
• W2923367087 creator A5003324655 @default.
• W2923367087 creator A5005912776 @default.
• W2923367087 creator A5006547437 @default.
• W2923367087 creator A5006712577 @default.
• W2923367087 creator A5007604294 @default.
• W2923367087 creator A5008015466 @default.
• W2923367087 creator A5009619083 @default.
• W2923367087 creator A5014839908 @default.
• W2923367087 creator A5016904876 @default.
• W2923367087 creator A5017328208 @default.
• W2923367087 creator A5020223648 @default.
• W2923367087 creator A5023902861 @default.
• W2923367087 creator A5024948228 @default.
• W2923367087 creator A5025511599 @default.
• W2923367087 creator A5028397596 @default.
• W2923367087 creator A5034274318 @default.
• W2923367087 creator A5036009814 @default.
• W2923367087 creator A5037915780 @default.
• W2923367087 creator A5038984237 @default.
• W2923367087 creator A5043694662 @default.
• W2923367087 creator A5047134346 @default.
• W2923367087 creator A5047435894 @default.
• W2923367087 creator A5049013376 @default.
• W2923367087 creator A5051155569 @default.
• W2923367087 creator A5052962511 @default.
• W2923367087 creator A5053071282 @default.
• W2923367087 creator A5055111767 @default.
• W2923367087 creator A5057162992 @default.
• W2923367087 creator A5058243253 @default.
• W2923367087 creator A5058357234 @default.
• W2923367087 creator A5067754981 @default.
• W2923367087 creator A5070375776 @default.
• W2923367087 creator A5073008346 @default.
• W2923367087 creator A5078807820 @default.
• W2923367087 creator A5080059818 @default.
• W2923367087 creator A5084238099 @default.
• W2923367087 creator A5086985238 @default.
• W2923367087 creator A5087387696 @default.
• W2923367087 creator A5088154882 @default.
• W2923367087 creator A5089948328 @default.
• W2923367087 creator A5090324173 @default.
• W2923367087 date "2019-12-01" @default.
• W2923367087 modified "2023-10-18" @default.
• W2923367087 title "Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer" @default.
• W2923367087 cites W1498673086 @default.
• W2923367087 cites W1546552389 @default.
• W2923367087 cites W1609712290 @default.
• W2923367087 cites W1904060183 @default.
• W2923367087 cites W1967187359 @default.
• W2923367087 cites W1980497534 @default.
• W2923367087 cites W2019607817 @default.
• W2923367087 cites W2044509984 @default.
• W2923367087 cites W2050211354 @default.
• W2923367087 cites W2065293650 @default.
• W2923367087 cites W2076178766 @default.
• W2923367087 cites W2086901484 @default.
• W2923367087 cites W2088540000 @default.
• W2923367087 cites W2093613683 @default.
• W2923367087 cites W2096198395 @default.
• W2923367087 cites W2110540279 @default.
• W2923367087 cites W2111662961 @default.
• W2923367087 cites W2121993228 @default.
• W2923367087 cites W2126177831 @default.
• W2923367087 cites W2132157071 @default.
• W2923367087 cites W2154149901 @default.
• W2923367087 cites W2154662831 @default.
• W2923367087 cites W2154803909 @default.
• W2923367087 cites W2160982674 @default.
• W2923367087 cites W2166084034 @default.
• W2923367087 cites W2169460814 @default.
• W2923367087 cites W2223370932 @default.
• W2923367087 cites W2292957477 @default.
• W2923367087 cites W2336821469 @default.
• W2923367087 cites W2386279287 @default.
• W2923367087 cites W2413097448 @default.
• W2923367087 cites W2416111151 @default.
• W2923367087 cites W2534288116 @default.
• W2923367087 cites W2581103010 @default.
• W2923367087 cites W2609015711 @default.
• W2923367087 cites W2655216406 @default.
• W2923367087 cites W2731518173 @default.
• W2923367087 cites W2766316939 @default.
• W2923367087 cites W2772237551 @default.
• W2923367087 cites W2775798067 @default.
• W2923367087 cites W2790922923 @default.
• W2923367087 cites W2899325153 @default.
• W2923367087 doi "https://doi.org/10.1200/po.18.00210" @default.
• W2923367087 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7446436" @default.
• W2923367087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32914023" @default.
• W2923367087 hasPublicationYear "2019" @default.
• W2923367087 type Work @default.
• W2923367087 sameAs 2923367087 @default.
• W2923367087 citedByCount "15" @default.
• W2923367087 countsByYear W29233670872019 @default.

• next